Therapy Areas: Oncology
Antengene announces inclusion on MSCI Global Small Cap Indexes - MSCI China Index constituent stocks
26 November 2021 -

Antengene Corporation Limited (SEHK: 6996.HK), a China-based biopharmaceutical company focused on discovering, developing and commercializing best-in-class therapeutics in haematology and oncology, announced on Thursday that according to the latest semi-annual review results of the world's leading index company MSCI, Antengene has been included in the MSCI Global Small Cap Indexes - MSCI China Index constituent stocks.

Accordingly relevant adjustments will be made after the market closes on 30 November 2021.

The firm has previously been included on the Hong Kong Composite Index and FTSE Global Equity Index Series. These listings are claimed to indicate the global capital markets' recognition of the company's growth prospects and its leadership position in the healthcare industry.

Login
Username:

Password:


Related Headlines